# Carlyle to acquire Baxter's Vantive kidney care segment for $3.8B

Baxter International Inc. signed a definitive agreement to divest its Kidney Care segment (Vantive) to funds managed by Carlyle for $3.8 billion. Baxter will receive approximately $3.5 billion in cash.

- Type: Acquisition
- Announced: 2024-08-13
- Where: United States
- Value: $3.80B
- Status: announced
- Products: kidney care products
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Carlyle Group](https://endata.com/companies/458.md) (acquirer)
- [Baxter International](https://endata.com/companies/20761.md) (target)

## Sources

- [carlyle.com](https://www.carlyle.com/media-room/news-release-archive/baxter-announces-definitive-agreement-divest-its-vantive-kidney), 2024-08-13: "Baxter International Inc. and funds managed by global investment firm Carlyle today announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter’s Kidney Care segment, to be named Vantive, for $3.8 billion."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.